These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 8643380)

  • 21. An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus.
    Watson KG; Brown RN; Cameron R; Chalmers DK; Hamilton S; Jin B; Krippner GY; Luttick A; McConnell DB; Reece PA; Ryan J; Stanislawski PC; Tucker SP; Wu WY; Barnard DL; Sidwell RW
    J Med Chem; 2003 Jul; 46(15):3181-4. PubMed ID: 12852746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binding of fluorescent dye to genomic RNA inside intact human rhinovirus after viral capsid penetration investigated by capillary electrophoresis.
    Kremser L; Okun VM; Nicodemou A; Blaas D; Kenndler E
    Anal Chem; 2004 Feb; 76(4):882-7. PubMed ID: 14961716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cutting edge: novel RNA ligands able to bind CD4 antigen and inhibit CD4+ T lymphocyte function.
    Kraus E; James W; Barclay AN
    J Immunol; 1998 Jun; 160(11):5209-12. PubMed ID: 9605115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A bipartite bacteriophage T4 SOC and HOC randomized peptide display library: detection and analysis of phage T4 terminase (gp17) and late sigma factor (gp55) interaction.
    Malys N; Chang DY; Baumann RG; Xie D; Black LW
    J Mol Biol; 2002 May; 319(2):289-304. PubMed ID: 12051907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isolation and characterization of 2'-fluoro-, 2'-amino-, and 2'-fluoro-/amino-modified RNA ligands to human IFN-gamma that inhibit receptor binding.
    Kubik MF; Bell C; Fitzwater T; Watson SR; Tasset DM
    J Immunol; 1997 Jul; 159(1):259-67. PubMed ID: 9200462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel species of human rhinoviruses in acute otitis media.
    Savolainen-Kopra C; Blomqvist S; Kilpi T; Roivainen M; Hovi T
    Pediatr Infect Dis J; 2009 Jan; 28(1):59-61. PubMed ID: 19057460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and evolution of artificial M13 coat proteins.
    Weiss GA; Sidhu SS
    J Mol Biol; 2000 Jun; 300(1):213-9. PubMed ID: 10864510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The human rhinovirus internal cis-acting replication element (cre) exhibits disparate properties among serotypes.
    McKnight KL
    Arch Virol; 2003 Dec; 148(12):2397-418. PubMed ID: 14648294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonneutralizing human rhinovirus serotype 2-specific monoclonal antibody 2G2 attaches to the region that undergoes the most dramatic changes upon release of the viral RNA.
    Hewat EA; Blaas D
    J Virol; 2006 Dec; 80(24):12398-401. PubMed ID: 17005641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cold case: are rhinoviruses perfectly adapted pathogens?
    Dreschers S; Dumitru CA; Adams C; Gulbins E
    Cell Mol Life Sci; 2007 Jan; 64(2):181-91. PubMed ID: 17131060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human Rhinovirus Inhibition Through Capsid "Canyon" Perturbation: Structural Insights into The Role of a Novel Benzothiophene Derivative.
    Agoni C; Ramharack P; Munsamy G; Soliman MES
    Cell Biochem Biophys; 2020 Mar; 78(1):3-13. PubMed ID: 31834576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pentamer channel stiffening model for drug action on human rhinovirus HRV-1A.
    Vaidehi N; Goddard WA
    Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2466-71. PubMed ID: 9122218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Computer simulation study of the binding of an antiviral agent to a sensitive and a resistant human rhinovirus.
    Lybrand TP; McCammon JA
    J Comput Aided Mol Des; 1989 Jan; 2(4):259-66. PubMed ID: 2541225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Common cold, uncommon variation.
    Poland GA; Barry MA
    N Engl J Med; 2009 May; 360(21):2245-6. PubMed ID: 19458372
    [No Abstract]   [Full Text] [Related]  

  • 35. Selection of high affinity RNA ligands to the bacteriophage R17 coat protein.
    Schneider D; Tuerk C; Gold L
    J Mol Biol; 1992 Dec; 228(3):862-9. PubMed ID: 1469719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Motion of an antiviral compound in a rhinovirus capsid under rotational symmetry boundary conditions.
    Yoneda S; Yoneda T; Kurihara Y; Umeyama H
    J Mol Graph Model; 2002 Aug; 21(1):19-27. PubMed ID: 12413027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monitoring RNA release from human rhinovirus by dynamic force microscopy.
    Kienberger F; Zhu R; Moser R; Blaas D; Hinterdorfer P
    J Virol; 2004 Apr; 78(7):3203-9. PubMed ID: 15016841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Advances in the research of human rhinovirus].
    Wang HH; Mao NY; Wang SZ; Wang ZX
    Bing Du Xue Bao; 2011 May; 27(3):294-7. PubMed ID: 21774257
    [No Abstract]   [Full Text] [Related]  

  • 39. Symposium on Rhinovirus pathogenesis. Charlottesville, December 14-15,1983.
    Acta Otolaryngol Suppl; 1984; 413():1-45. PubMed ID: 6598255
    [No Abstract]   [Full Text] [Related]  

  • 40. Selection of high affinity RNA ligands to a synthetic peptide of human rhinovirus 14 coat protein.
    De Beuckelaer A; Fürste JP
    Nucleic Acids Symp Ser; 1995; (33):23. PubMed ID: 8643380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.